Ian Mortimer

Xenon Pharmaceuticals Inc.Xenon Pharmaceuticals Inc.

Insider activity · 24 months1 buy2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 1 saleDec 25 · 0 buys · 1 saleJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 1 buy · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€989k

▼ Sales (2 ops.)

€560k

Latest filing published 01 Oct 2026 for Xenon Pharmaceuticals Inc., €989k. Read the official filing

Filing timeline

BuySale

Ian Mortimer

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Xenon Pharmaceuticals Inc. 1 purchase · last 01 Oct 2026

Ian Mortimer: trading record in brief

Ian Mortimer appears in our data through filings on Xenon Pharmaceuticals Inc. shares, published by SEC (Form 4). We count 9 filings; the first trade dates from 24 May 2023 and the latest from 30 September 2026.

Market trades split into 1 purchase (€989k) and 2 sales (€560k). The net balance comes to €429k on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 6 option exercises. 2026 to date brings 1 purchase and no sales.

The newest entry dates from 1 October 2026: an open-market purchase of €989k, in Xenon Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.